RT Journal Article
SR Electronic
T1 Sustained patient use and improved outcomes with digital transformation of a COPD service: RECEIVER trial and DYNAMIC-SCOT COVID-19 scale-up response
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.04.22273427
DO 10.1101/2022.04.04.22273427
A1 A Taylor
A1 A Cushing
A1 M Dow
A1 J Anderson
A1 G McDowell
A1 S Lua
A1 M Manthe
A1 S Padmanabhan
A1 S Burns
A1 P McGinness
A1 DJ Lowe
A1 C Carlin
YR 2022
UL http://medrxiv.org/content/early/2022/04/05/2022.04.04.22273427.abstract
AB Introduction LenusCOPD has been co-designed to enable digital transformation of COPD services for proactive preventative care. Patient-facing progressive web application, clinician dashboard and support website integrate patient-reported outcomes (PROs), self-management resources, structured clinical summary, wearable and home NIV data with asynchronous patient-clinician messaging. We commenced the implementation-effectiveness observational cohort RECEIVER trial in September 2019, with the primary endpoint of sustained patient usage and secondary endpoints including admissions, mortality, exacerbations, service workload and quality of life. We paused recruitment in March 2021 and provided LenusCOPD as routine care in the “DYNAMIC-SCOT” COVID-19 response service scale-up.Methods 83 RECEIVER trial participants and 142 DYNAMIC-SCOT participants had completed minimum 1 year follow-up when we censored data on 31st August 2021. We established a control cohort with 5 patients matched per RECEIVER participant from de-identified contemporary routine clinical data.Results Sustained patient app utilisation was noted in both cohorts. Median time to admission or death was 43 days in control, 338 days in RECEIVER and 400 days in DYNAMIC-SCOT participants who had had a respiratory-related admission in the preceding year. The 12-month risk of admission or death was 74% in control patients, 53% in RECEIVER and 47% in the DYNAMIC-SCOT sub-cohort participants. There was a median of 2.5 COPD exacerbations per patient per year with stable quality of life across follow up and a manageable workload for clinical users.Conclusions A high proportion of people continued to use the co-designed LenusCOPD application during extended follow-up. Outcome data supports scale-up of this digital service transformation.What is the key question?Can sustained patient interaction and improved patient outcomes be achieved with digital transformation of a COPD service?What is the bottom line?Participants continue to use the LenusCOPD patient app, with an average of 3-3.5 interactions per person per week sustained >1-year post-onboarding. COPD- related hospital admissions and occupied bed days were reduced following LenusCOPD onboarding in participants with a history of a severe exacerbation in the previous year, with a median time to readmission of 380 days compared with 50 days in a contemporary matched control patient cohort.Why read on?Feasibility and utility results support scale-up adoption of these digital tools, to support optimised co-management of COPD and other long-term conditions within a continuous implementation-evaluation framework. This will establish a test-bed infrastructure for additional innovations including artificial intelligence-insights for MDT decision support.Competing Interest StatementA Cushing, M Dow, S Burns are employees and P McGinness is director of LenusHealth, which is the manufacturer of LenusCOPD. The other authors have no conflicts of interest to declare. Clinical TrialNCT04240353Clinical Protocols https://bmjopenrespres.bmj.com/content/8/1/e000905 Funding StatementThe DYNAMIC project (development of LenusCOPD tools, RECEIVER trial) was funded by a digital health technology catalyst award from InnovateUK. The DYNAMIC-SCOT scale-up project was funded by award from Scottish Government Technology Enabled Care and Modernising Patient Pathway Programs.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The West of Scotland Research Ethics Service gave ethical approval for this work, reference 19/WS/0072. NHS Greater Glasgow & Clyde Local Privacy and Advisory Committee gave permission for the use of de-identified SafeHaven data for this work, reference GSH/19/RM003I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://support.nhscopd.scot